Halozyme Therapeutics HALO Enterprise value

Enterprise value at other companies

West Pharmaceutical ServicesWST

$25.24B+59.8%

AMP

Amphastar PharmaceuticalsAMPH

$1.35B-16.7%

AptarGroupATR

$9.25B-13.9%

Opko HealthOPK

$1.18B+9.8%

Amneal Pharmaceuticals, Inc.AMRX

$7.97B+71.3%

Aquestive Therapeutics, Inc.AQST

$460.11M+65.5%

FAQ

What is Halozyme Therapeutics's enterprise value?

Halozyme Therapeutics (HALO) reported enterprise value of $11.3B in Q2 2026.

How has Halozyme Therapeutics's enterprise value changed year-over-year?

Halozyme Therapeutics's enterprise value increased by 39.2% year-over-year, from $8.12B to $11.3B.

What is the long-term trend for Halozyme Therapeutics's enterprise value?

Over 5 years (2020 to 2025), Halozyme Therapeutics's enterprise value has grown at a 10.1% compound annual growth rate (CAGR), from $6.15B to $9.96B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.